Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market

TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"). The agreement grants GV the worldwide rights to apply Yike's breakthrough stem cell technology, which has demonstrated significant potential in advancing treatments for diabetes and with other regenerative medicine innovations.

Read more at prnewswire.com